Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable.
Category: Kenvue Inc
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion
The owner of Kleenex and Huggies will acquire the company that has fought claims by the Trump administration that a common pain reliever is linked to harmful side effects.
-
Texas Sues Tylenol Makers, Claiming They Hid Autism Risks
The lawsuit follows claims by President Trump that linked use by pregnant women of acetaminophen to autism, a connection that is unproven.
-
Neutrogena Recalls Makeup Wipes Over Bacterial Contamination Concerns
The recalled wipes were distributed in Florida, Georgia, South Carolina and Texas, according to the Food and Drug Administration.
-
Johnson & Johnson Sued in U.K. Over Baby Powder Cancer Claims
More than 3,000 people in Britain have joined a lawsuit accusing the company of knowing that its baby powder contained carcinogenic fibers, including asbestos.
-
Taking Too Much Tylenol Has Proven Risks. Trump Didn’t Talk About Those.
Acetaminophen’s link to autism is unproven. But hundreds of Americans accidentally overdose on the drug each year, suffering liver damage that can require a transplant or even be fatal.
-
F.D.A.’s Approval of Drug for Autism Upends Review Process
The agency revived an old treatment for cancer patients, unilaterally approving it for a subset of people with autism. Experts worry that the narrower scope will get lost in the hype.